News
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Clinical Trials Arena on MSN1d
Boehringer Ingelheim begins Phase II trial of BI 1584862 for geographic atrophyThe study aims to identify the optimal dose of BI 1584862 and observe its impact on improving GA patients' eyes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback